📰 Arcus Bioscience News
Page 3 - Arcus Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Arcus Bioscience. Real-time updates on events, politics, business and more.
January 26, 2024
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of...
January 16, 2024
Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A...
December 8, 2023
Merck said on Thursday a combination treatment testing a new type of immunotherapy failed to significantly slow disease progression in lung cancer patients who did not respond to previous treatments.
December 4, 2023
– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – ...
November 27, 2023
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the...
November 14, 2023
13.11.2023 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s ...
November 8, 2023
Data were presented from the ongoing EDGE-Gastric Phase 2 study in first-line upper GI cancers at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Plenary Series; domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first-to-...
November 7, 2023
– Preliminary data from Arm A1 of the Phase 2 EDGE-Gastric study showed promising ORR and six-month PFS results, irrespective of PD-L1 expression –– Domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first to market for these cancers –– Detailed...
November 7, 2023
07.11.2023 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended ...